15 Jan 2024 • A landmark study from Tata Memorial Centre, Mumbai which was recently published in the Lancet, brings in a significant advancement in managing chemotherapy-induced nausea.

As per their findings, low-dose olanzapine (2.5 mg) was found to be non-inferior to the standard 10 mg dose in preventing nausea and vomiting in patients undergoing highly emetogenic chemotherapy, primarily for breast cancer.

The low-dose regimen effectively controlled emetic episodes without the use of rescue medications, while significantly reducing the occurrence of daytime somnolence.

These findings, marking a pivotal shift, suggest that low-dose olanzapine should be considered as a new standard in antiemetic care for chemotherapy patients.

Source: The Lancet | Read full story